Compare Panacea Biotech with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs BIOCON - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH BIOCON PANACEA BIOTECH/
BIOCON
 
P/E (TTM) x 10.6 22.5 47.0% View Chart
P/BV x 2.2 3.0 75.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   BIOCON
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
BIOCON
Mar-18
PANACEA BIOTECH/
BIOCON
5-Yr Chart
Click to enlarge
High Rs3541,188 29.8%   
Low Rs138305 45.3%   
Sales per share (Unadj.) Rs74.668.7 108.5%  
Earnings per share (Unadj.) Rs6.77.6 88.4%  
Cash flow per share (Unadj.) Rs15.514.0 110.9%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs57.286.3 66.3%  
Shares outstanding (eoy) m61.25600.00 10.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.310.9 30.4%   
Avg P/E ratio x36.898.9 37.2%  
P/CF ratio (eoy) x15.953.4 29.7%  
Price / Book Value ratio x4.38.6 49.7%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m15,061447,900 3.4%   
No. of employees `0002.36.1 37.6%   
Total wages/salary Rs m1,4719,311 15.8%   
Avg. sales/employee Rs Th1,973.66,705.8 29.4%   
Avg. wages/employee Rs Th635.61,514.2 42.0%   
Avg. net profit/employee Rs Th176.8736.9 24.0%   
INCOME DATA
Net Sales Rs m4,56741,234 11.1%  
Other income Rs m452,062 2.2%   
Total revenues Rs m4,61243,296 10.7%   
Gross profit Rs m2,0308,291 24.5%  
Depreciation Rs m5403,851 14.0%   
Interest Rs m1,048615 170.5%   
Profit before tax Rs m4865,887 8.3%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m771,569 4.9%   
Profit after tax Rs m4094,531 9.0%  
Gross profit margin %44.420.1 221.0%  
Effective tax rate %15.926.7 59.5%   
Net profit margin %9.011.0 81.5%  
BALANCE SHEET DATA
Current assets Rs m2,41541,486 5.8%   
Current liabilities Rs m9,07721,413 42.4%   
Net working cap to sales %-145.948.7 -299.7%  
Current ratio x0.31.9 13.7%  
Inventory Days Days6564 101.8%  
Debtors Days Days7194 75.3%  
Net fixed assets Rs m8,33350,661 16.4%   
Share capital Rs m613,000 2.0%   
"Free" reserves Rs m3,44348,808 7.1%   
Net worth Rs m3,50451,808 6.8%   
Long term debt Rs m46117,898 2.6%   
Total assets Rs m13,75599,897 13.8%  
Interest coverage x1.510.6 13.8%   
Debt to equity ratio x0.10.3 38.1%  
Sales to assets ratio x0.30.4 80.4%   
Return on assets %10.65.2 205.7%  
Return on equity %11.78.7 133.5%  
Return on capital %38.79.6 401.7%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Exports (fob) Rs m954NA-   
Imports (cif) Rs m372NA-   
Fx inflow Rs m1,20312,058 10.0%   
Fx outflow Rs m4677,348 6.4%   
Net fx Rs m7364,710 15.6%   
CASH FLOW
From Operations Rs m1,0496,621 15.8%  
From Investments Rs m-54-6,840 0.8%  
From Financial Activity Rs m-1,011-2,397 42.2%  
Net Cashflow Rs m-20-2,612 0.8%  

Share Holding

Indian Promoters % 74.5 40.4 184.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.6 8.4 7.1%  
FIIs % 1.3 10.7 12.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 19.9 118.6%  
Shareholders   10,259 109,995 9.3%  
Pledged promoter(s) holding % 35.1 0.0 87,675.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  SHASUN PHARMA  PFIZER  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 22, 2019 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS